{{Rsnum
|rsid=35964658
|Chromosome=4
|position=141758435
|Orientation=plus
|GMAF=0.1942
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 82.1 | 17.9 | 0.0
| HCB | 36.5 | 43.1 | 20.4
| JPT | 33.6 | 49.6 | 16.8
| YRI | 93.2 | 6.8 | 0.0
| ASW | 82.5 | 17.5 | 0.0
| CHB | 36.5 | 43.1 | 20.4
| CHD | 23.9 | 52.3 | 23.9
| GIH | 74.3 | 22.8 | 3.0
| LWK | 95.5 | 4.5 | 0.0
| MEX | 44.8 | 44.8 | 10.3
| MKK | 88.5 | 11.5 | 0.0
| TSI | 91.2 | 8.8 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs35964658
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: G, MAF= 0.12, combined P value= 4.01E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470169
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs35964658
|overall_frequency_n=19
|overall_frequency_d=128
|overall_frequency=0.148438
|n_genomes=14
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}